NASDAQ: DMRADamora Therapeutics Inc Stock
$26.33-0.04 (-0.15%)
Updated Mar 13, 2026
DMRA Price
$26.33
Fair Value Price
$12.19
Market Cap
$34.95M
52 Week Low
$2.01
52 Week High
$38.33
P/E
-2.17x
P/B
4.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.34
Operating Cash Flow
-$12M
Beta
1.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DMRA Overview
Galecto, Inc. is a clinical-stage biotechnology company developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Its research centers on the use of modulators proteins galectin-3 and LOXL-2. The company was founded in 2011 and is based in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DMRA's potential to beat the market
- DMRA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DMRA
RankedUnranked of 469
RankedUnranked of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.51 | A | |
| $32.13 | A | |
| $178.55 | A |
Be the first to know about important DMRA news, forecast changes, insider trades & much more!
DMRA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DMRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMRA ($26.33) is overvalued by 116.05% relative to our estimate of its Fair Value price of $12.19 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DMRA ($26.33) is not significantly undervalued (116.05%) relative to our estimate of its Fair Value price of $12.19 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DMRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DMRA due diligence checks available for Premium users.
Valuation
DMRA fair value
Fair Value of DMRA stock based on Discounted Cash Flow (DCF)
Price
$26.33
Fair Value
$12.19
Overvalued by
116.05%
DMRA ($26.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DMRA ($26.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DMRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DMRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.17x
Industry
29.3x
Market
31.8x
DMRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.36x
Industry
4.7x
DMRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DMRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
DMRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.7M
Liabilities
$2.7M
Debt to equity
0.34
DMRA's short-term assets ($9.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMRA's short-term assets ($9.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DMRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.6M
Investing
$0.0
Financing
$0.0
DMRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DMRA vs Biotech Stocks
Damora Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.